ELCC 2026: Key Trial Updates in Lung Cancer

In this MEDtalk from ELCC 2026, Bjørn Henning Grønberg, MD, Professor and Consultant in Oncology at the Norwegian University of Science and Technology, Norway, presents selected lung cancer highlights from the congress. Among these are a study in which combined radiotherapy and immunotherapy were associated with improved time to progression, without a survival benefit to date. He also reviews early data on KRASG12D inhibitors and combination strategies with osimertinib in EGFR-mutated NSCLC, along with promising results from a novel antibody–drug conjugate in small cell lung cancer and data on the timing of immunotherapy.